Pierre Tennstedt

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2029895/publications.pdf

Version: 2024-02-01

		126907	1	33252	
135	3,734	33		59	
papers	citations	h-index		g-index	
135	135	135		5966	
155	133	133		3700	
all docs	docs citations	times ranked		citing authors	

#	Article	IF	CITATIONS
1	CHD1 loss negatively influences metastasis-free survival in R0-resected prostate cancer patients and promotes spontaneous metastasis in vivo. Cancer Gene Therapy, 2022, 29, 49-61.	4.6	3
2	Cohort study of oligorecurrent prostate cancer patients: Oncological outcomes of patients treated with salvage lymph node dissection via PSMA radioguided surgery Journal of Clinical Oncology, 2022, 40, 106-106.	1.6	0
3	Cohort study of patients with oligorecurrent prostate cancer: Oncological outcomes of patients treated with salvage lymph node dissection via PSMA radioguided surgery Journal of Clinical Oncology, 2022, 40, 5009-5009.	1.6	O
4	Significant reduction of lymphoceles after radical prostatectomy and pelvic lymph node dissection. BJU International, 2021, 128, 728-733.	2.5	2
5	Circulating Vitamin D and Selenium Levels and Outcome in Prostate Cancer Patients: Lessons from the MARTINI-Lifestyle Cohort. European Urology Focus, 2021, 7, 973-979.	3.1	5
6	A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology. PLoS ONE, 2021, 16, e0259093.	2.5	4
7	Poor Adherence to International Cancer Prevention Recommendations Among Patients With Prostate Cancer: First Results From the MARTINI-Lifestyle Cohort. European Urology Focus, 2020, 6, 935-940.	3.1	7
8	Tumor-Associated Release of Prostatic Cells into the Blood after Transrectal Ultrasound-Guided Biopsy in Patients with Histologically Confirmed Prostate Cancer. Clinical Chemistry, 2020, 66, 161-168.	3.2	21
9	Development and validation of a novel multivariate risk score to guide biopsy decision for the diagnosis of clinically significant prostate cancer. BJUI Compass, 2020, 1, 15-20.	1.3	25
10	Prognostic factors for lymphedema in patients with locally advanced head and neck cancer after combined radio(chemo)therapy-results of a longitudinal study. Oral Oncology, 2020, 109, 104856.	1.5	14
11	Subcellular Compartmentalization of Survivin is Associated with Biological Aggressiveness and Prognosis in Prostate Cancer. Scientific Reports, 2020, 10, 3250.	3.3	18
12	Comparison of Cognitive Function After Robot-Assisted Prostatectomy and Open Retropubic Radical Prostatectomy: A Prospective Observational Single-Center Study. Urology, 2020, 139, 110-117.	1.0	7
13	Validation of the updated eighth edition of AJCC for prostate cancer: Removal of pT2 substages – Does extent of tumor involvement matter?. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 637.e1-637.e7.	1.6	1
14	Predictors of short and long term urinary incontinence after radical prostatectomy in prostate MRI: Significance and reliability of standardized measurements. European Journal of Radiology, 2019, 120, 108668.	2.6	13
15	Prostate cancer prognosis in men with other malignancies prior to radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 575.e1-575.e7.	1.6	4
16	A comparative study of robotâ€assisted and open radical prostatectomy in 10Â790 men treated by highly trained surgeons for both procedures. BJU International, 2019, 123, 1031-1040.	2.5	76
17	Thrombospondin 1 and cathepsin D improve prostate cancer diagnosis by avoiding potentially unnecessary prostate biopsies. BJU International, 2019, 123, 826-833.	2.5	25
18	Obesity paradox in prostate cancer: increased body mass index was associated with decreased risk of metastases after surgery in 13,667 patients. World Journal of Urology, 2018, 36, 1067-1072.	2.2	18

#	Article	IF	CITATIONS
19	Accuracy of multiparametric MR imaging with PI-RADS V2 assessment in detecting infiltration of the neurovascular bundles prior to prostatectomy. European Journal of Radiology, 2018, 98, 187-192.	2.6	9
20	Effect of repeat prostate biopsies on functional outcomes after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 91.e17-91.e22.	1.6	4
21	Prostate cancer rates in patients with initially negative elastography-targeted biopsy vs. systematic biopsy. World Journal of Urology, 2018, 36, 623-628.	2.2	5
22	Return to work following robot-assisted laparoscopic and open retropubic radical prostatectomy: A single-center cohort study to compare duration of sick leave. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 309.e1-309.e6.	1.6	8
23	BCL2-overexpressing prostate cancer cells rely on PARP1-dependent end-joining and are sensitive to combined PARP inhibitor and radiation therapy. Cancer Letters, 2018, 423, 60-70.	7.2	31
24	Validation of Cyclic Adenosine Monophosphate Phosphodiesterase-4D7 for its Independent Contribution to Risk Stratification in a Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes. European Urology Focus, 2018, 4, 376-384.	3.1	12
25	Development and validation of a renal risk score in ANCA-associated glomerulonephritis. Kidney International, 2018, 94, 1177-1188.	5.2	179
26	The Prognostic PDE4D7 Score in a Diagnostic Biopsy Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes. Prostate Cancer, 2018, 2018, 1-11.	0.6	10
27	Radical prostatectomy neutralizes obesity-driven risk of prostate cancer progression. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 243-249.	1.6	11
28	Defining biochemical recurrence after radical prostatectomy and timing of early salvage radiotherapy. Strahlentherapie Und Onkologie, 2017, 193, 692-699.	2.0	19
29	MP28-03 ALTERATION OF METASTATIC BEHAVIOR BY SHRNA MEDIATED KNOCKDOWN (KD) OF CHD1 IN HUMAN PROSTATE XENOGRAFT TUMORS AND CLINICAL OUTCOME OF PATIENTS WITH CHD1 DELETION. Journal of Urology, 2017, 197, .	0.4	0
30	Short- and Long-term Functional Outcomes and Quality of Life after Radical Prostatectomy: Patient-reported Outcomes from a Tertiary High-volume Center. European Urology Focus, 2017, 3, 615-620.	3.1	44
31	MP47-04 OBESITY WAS ASSOCIATED WITH IMPROVED METASTASES-FREE SURVIVAL AFTER SURGERY IN 13,667 PROSTATE CANCER PATIENTS. Journal of Urology, 2017, 197, .	0.4	O
32	MP03-12 ACCURACY OF MULTIPARAMETRIC MR IMAGING WITH PI-RADS V2 ASSESSMENT IN DETECTING INFILTRATIONS OF THE NEUROVASCULAR BUNDLES PRIOR TO PROSTATECTOMY. Journal of Urology, 2017, 197, .	0.4	0
33	MP47-03 IMPACT OF ADDITIONAL RADIATION AND/OR ADT ON FUNCTIONAL OUTCOMES AFTER RADICAL PROSTATECTOMY. Journal of Urology, 2017, 197, .	0.4	O
34	MP97-14 FUNCTIONAL OUTCOME OF RADICAL PROSTATECTOMY AFTER REPEAT BIOPSY. Journal of Urology, 2017, 197, .	0.4	0
35	MP28-05 A COMBINATION OF NEW PROTEIN BIOMARKERS REDUCES UNNEEDED PROSTATE BIOPSIES AND IMPROVES THE DETECTION OF PROSTATE CANCER: FINDINGS OF A RECENT STUDY. Journal of Urology, 2017, 197, .	0.4	1
36	Adjuvant radiation therapy is associated with better oncological outcome compared with salvage radiation therapy in patients with <scp>pN</scp> 1 prostate cancer treated with radical prostatectomy. BJU International, 2017, 119, 717-723.	2.5	39

#	Article	IF	Citations
37	The Impact of Repeat Prostate Biopsies on Oncologic, Pathological and Perioperative Outcomes after Radical Prostatectomy. Journal of Urology, 2017, 197, 103-108.	0.4	7
38	Functional Outcomes and Quality of Life After Radical Prostatectomy Only Versus a Combination of Prostatectomy with Radiation and Hormonal Therapy. European Urology, 2017, 71, 330-336.	1.9	57
39	ABO/Rhesus Blood Group Does Not Influence Clinicopathological Tumor Characteristics or Oncological Outcome in Patients Undergoing Radical Prostatectomy. Frontiers in Surgery, 2017, 4, 75.	1.4	1
40	Development and clinical testing of individual immunoassays for the quantification of serum glycoproteins to diagnose prostate cancer. PLoS ONE, 2017, 12, e0181557.	2.5	15
41	Validation of cAMP phosphodiesterase-4D7 (PDE4D7) for its independent contribution to risk stratification in a prostate cancer patient cohort with longitudinal biological outcomes Journal of Clinical Oncology, 2017, 35, 5069-5069.	1.6	0
42	Survival and overall treatment time after postoperative radio(chemo)therapy in patients with head and neck cancer. Head and Neck, 2016, 38, 1058-1065.	2.0	32
43	Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients. Scientific Reports, 2016, 6, 39736.	3.3	96
44	MP57-06 RADICAL PROSTATECTOMY AFTER REPEAT BIOPSY: ONCOLOGICAL AND PERIOPERATIVE OUTCOME. Journal of Urology, 2016, 195, .	0.4	0
45	Differences in Patient Characteristics Among Men Choosing Open or Robot-Assisted Radical Prostatectomy in Contemporary Practice at a European High-Volume Center. Urologia Internationalis, 2016, 97, 8-15.	1.3	5
46	PD03-12 APPLYING SEVEN CONTEMPORARY ACTIVE SURVEILLANCE PROTOCOLS TO PATIENTS UNDERGOING RADICAL PROSTATECTOMY: SIGNIFICANT DIFFERENCES IN MIDTERM ONCOLOGICAL OUTCOMES. Journal of Urology, 2016, 195, .	0.4	0
47	Impact of surgeon-defined capsular incision during radical prostatectomy on biochemical recurrence rates. World Journal of Urology, 2016, 34, 1547-1553.	2.2	2
48	Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 235.e11-235.e16.	1.6	62
49	The zinc-finger transcription factor SALL4 is frequently expressed in human cancers: association with clinical outcome in squamous cell carcinoma but not in adenocarcinoma of the esophagus. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 483-492.	2.8	14
50	True targeting-derived prostate biopsy: HistoScanningâ,,¢ remained inadequate despite advanced technical efforts. World Journal of Urology, 2016, 34, 495-500.	2.2	7
51	Additional elastography-targeted biopsy improves the agreement between biopsy Gleason grade and Gleason grade at radical prostatectomy. World Journal of Urology, 2016, 34, 805-810.	2.2	7
52	Nerve-sparing Surgery Technique, Not the Preservation of the Neurovascular Bundles, Leads to Improved Long-term Continence Rates After Radical Prostatectomy. European Urology, 2016, 69, 584-589.	1.9	119
53	Toxicity in a multimodality approach of radical prostatectomy with radiation and hormonal therapy Journal of Clinical Oncology, 2016, 34, 107-107.	1.6	0
54	MP83-06 IS INVERSE STAGE MIGRATION A SUSTAINING PHENOMENON IN PATIENTS UNDERGOING RADICAL PROSTATECTOMY?. Journal of Urology, 2015, 193, .	0.4	0

#	Article	IF	CITATIONS
55	MP82-05 A COMPARISON OF DIFFERENT TREATMENT OPTIONS FOR LYMPH NODE-POSITIVE PROSTATE CANCER AT RADICAL PROSTATECTOMY. Journal of Urology, 2015, 193, .	0.4	2
56	Oncological outcome after radical prostatectomy: Marital status does not make a difference. International Journal of Urology, 2015, 22, 484-489.	1.0	5
57	MP55-08 GENOMIC DELETION OF CHROMOSOME 12P IS AN INDEPENDENT PROGNOSTIC MARKER IN PROSTATE CANCER. Journal of Urology, 2015, 193, .	0.4	0
58	MP83-05 THE EFFECT OF NERVE-SPARING ON URINARY CONTINENCE AFTER RADICAL PROSTATECTOMY: IS IT THE PRESERVATION OF THE NEUROVASCULAR BUNDLES OR THE SURGICAL TECHNIQUE WHICH LEADS TO IMPROVED CONTINENCE RATES?. Journal of Urology, 2015, 193, .	0.4	0
59	Concurrent deletion of 16q23 and PTEN is an independent prognostic feature in prostate cancer. International Journal of Cancer, 2015, 137, 2354-2363.	5.1	39
60	Prediction of Significant Prostate Cancer at Prostate Biopsy and Per Core Detection Rate of Targeted and Systematic Biopsies Using Real-Time Shear Wave Elastography. Urologia Internationalis, 2015, 95, 189-196.	1.3	23
61	Use of Phosphodiesterase Type 5 Inhibitors May Adversely Impact Biochemical Recurrence after Radical Prostatectomy. Journal of Urology, 2015, 193, 479-483.	0.4	46
62	External Validation of the CAPRA-S Score to Predict Biochemical Recurrence, Metastasis and Mortality after Radical Prostatectomy in a European Cohort. Journal of Urology, 2015, 193, 1970-1975.	0.4	50
63	Additional androgen deprivation makes the difference. Strahlentherapie Und Onkologie, 2015, 191, 330-337.	2.0	13
64	MP78-18 IMPACT OF CAPSULAR INCISION DURING RADICAL PROSTATECTOMY ON BIOCHEMICAL RECURRENCE RATES. Journal of Urology, 2015, 193, .	0.4	0
65	Tumor volume in insignificant prostate cancer: Increasing threshold gains increasing risk. Prostate, 2015, 75, 45-49.	2.3	22
66	Safe-R: a novel score, accounting for oncological safe nerve-sparing at radical prostatectomy for localized prostate cancer. World Journal of Urology, 2015, 33, 77-83.	2.2	2
67	Redefining postprostatectomy biochemical progression: The significance of a PSA cutoff below 0.2 ng/ml—Results from two retrospective series with and without salvage radiotherapy Journal of Clinical Oncology, 2015, 33, 153-153.	1.6	O
68	Patterns of ALK expression in different human cancer types. Journal of Clinical Pathology, 2014, 67, 477-481.	2.0	5
69	Carbonic anhydrase <scp>IX</scp> is strongly overexpressed in adenocarcinoma <i>inÂsitu</i> of the cervix uteri. Histopathology, 2014, 64, 600-602.	2.9	5
70	Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer. Modern Pathology, 2014, 27, 1612-1620.	5.5	69
71	Open and robotâ€assisted radical retropubic prostatectomy in men receiving ongoing lowâ€dose aspirin medication: revisiting an old paradigm?. BJU International, 2014, 114, 396-403.	2.5	29
72	Functional and oncological outcomes of patients aged <50 years treated with radical prostatectomy for localised prostate cancer in a <scp>E</scp> uropean population. BJU International, 2014, 114, 38-45.	2.5	37

#	Article	IF	CITATIONS
73	PD14-12 CLAVIEN IIIB COMPLICATIONS AFTER OPEN RETROPUBIC AND ROBOTIC-ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY IN A SINGLE HIGH-VOLUME CENTER. Journal of Urology, 2014, 191, .	0.4	1
74	MP52-17 RECURRENT CHROMOSOMAL DELETIONS STATUS OBTAINED ON TISSUE CORES IS HIGHLY CORRELATED WITH LOCAL INVASIVE AND SYSTEMIC PROSTATE CANCER GROWTH. Journal of Urology, 2014, 191, .	0.4	0
75	MP58-06 BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY: IS EVERY PATIENT WITH A PSA OF 0.1NG/ML REALLY RECURRING?. Journal of Urology, 2014, 191, .	0.4	O
76	MP67-09 RISK ASSESSMENT TO PREDICT A POSITIVE BIOPSY USING SHEARWAVE ELASTOGRAPHY Journal of Urology, 2014, 191, .	0.4	0
77	MP67-13 DOES HISTOSCANNING (â,,¢) PREDICT POSITIVE RESULTS IN PROSTATE BIOPSY? A RETROSPECTIVE ANALYSIS OF 1,188 SEXTANTS OF THE PROSTATE. Journal of Urology, 2014, 191, .	0.4	O
78	TMPRSS2-ERG Fusions Are Strongly Linked to Young Patient Age in Low-grade Prostate Cancer. European Urology, 2014, 66, 978-981.	1.9	54
79	Histoscanning Has Low Sensitivity and Specificity for Seminal Vesicle Invasion. Urology, 2014, 84, 1168-1171.	1.0	5
80	PD19-10 A POSITIVE SURGICAL MARGIN SIGNIFICANTLY INCREASES OVERALL MORTALITY AFTER RADICAL PROSTATECTOMY. Journal of Urology, 2014, 191, .	0.4	0
81	MP79-15 PROGNOSTIC UTILITY OF THE CELL CYCLE PROGRESSION (CCP) SCORE GENERATED FROM NEEDLE BIOPSY IN MEN TREATED WITH PROSTATECTOMY. Journal of Urology, 2014, 191, .	0.4	o
82	MP51-18 ADJUVANT AND SALVAGE RADIOTHERAPY AFTER RADICAL PROSTATECTOMY DOES NOT COMPROMISE URINARY CONTINENCE. Journal of Urology, 2014, 191, .	0.4	0
83	PD14-08 AMOUNT OF DISSECTED LYMPH NODES DURING RADICAL PROSTATECTOMY DOES NOT DEPEND ON SURGICAL APPROACH IN A SINGLE HIGH-VOLUME CENTER. Journal of Urology, 2014, 191, .	0.4	2
84	PD15-05 PREDICTION OF LOCALLY ADVANCED PROSTATE CANCER AND TUMOR VOLUME WITH SHEARWAVE ELASTOGRAPHY PRIOR TO RADICAL PROSTATECTOMY: IMPACT ON ACTIVE SURVEILLANCE AND SELECTION FOR PROSTATE BIOPSY. Journal of Urology, 2014, 191, .	0.4	0
85	MP53-15 SHEARWAVE ELASTOGRAPHY FOR LOCALIZATION OF PROSTATE CANCER LESIONS AND ASSESSMENT OF ELASTICITY THRESHOLDS: IMPLICATIONS FOR TARGETED BIOPSIES AND ACTIVE SURVEILLANCE PROTOCOLS. Journal of Urology, 2014, 191, .	0.4	O
86	Prognostic Utility of the Cell Cycle Progression Score Generated from Biopsy in Men Treated with Prostatectomy. Journal of Urology, 2014, 192, 409-414.	0.4	180
87	A Feasible and Time-efficient Adaptation of NeuroSAFE for da Vinci Robot-assisted Radical Prostatectomy. European Urology, 2014, 66, 138-144.	1.9	94
88	Patterns of TPD52 overexpression in multiple human solid tumor types analyzed by quantitative PCR. International Journal of Oncology, 2014, 44, 609-615.	3.3	48
89	Effect of adjuvant and salvage radiotherapy after radical prostatectomy on urinary continence Journal of Clinical Oncology, 2014, 32, 100-100.	1.6	1
90	Prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with prostatectomy Journal of Clinical Oncology, 2014, 32, 17-17.	1.6	0

#	Article	IF	Citations
91	Correlation between recurrent chromosomal deletions status obtained on tissue cores and local invasive and systemic prostate cancer growth Journal of Clinical Oncology, 2014, 32, 24-24.	1.6	0
92	A feasible and time-efficient adaption of the neurosafe intraoperative frozen section technique to robotic-assisted radical prostatectomy Journal of Clinical Oncology, 2014, 32, 147-147.	1.6	0
93	Prognostic value of alpha-methyl CoA racemase (AMACR) expression in renal cell carcinoma. World Journal of Urology, 2013, 31, 847-853.	2.2	13
94	Large-scale independent validation of the nuclear factor-kappa B p65 prognostic biomarker in prostate cancer. European Journal of Cancer, 2013, 49, 2441-2448.	2.8	40
95	360 SAFE-R: A NOVEL SCORE, ACCOUNTING FOR ONCOLOGICAL SAFE NERVE-SPARING. Journal of Urology, 2013, 189, .	0.4	0
96	High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer. European Journal of Cancer, 2013, 49, 1273-1279.	2.8	101
97	V2160 INTRAOPERATIVE NEUROVASCULAR STRUCTURE-ADJACENT FROZEN-SECTION EXAMINATION (NEUROSAFE) INCREASES NERVE-SPARING FREQUENCY AND REDUCES POSITIVE SURGICAL MARGINS IN DAVINCI-ROBOT-ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY (DVP): EXPERIENCE AFTER 1157 CONSECUTIVE PATIENTS, Journal of Urology, 2013, 189, .	0.4	0
98	985 VALUE OF CELL CYCLE PROGRESSION (CCP) SCORE TO PREDICT BIOCHEMICAL RECURRENCE AND DEFINITIVE POST-SURGICAL PATHOLOGY. Journal of Urology, 2013, 189, .	0.4	0
99	356 RISK-FACTORS FOR BIOCHEMICAL RECURRENCE- AND CLINICAL METASTASIS-FREE SURVIVAL IN D'AMICO HIGH-RISK PATIENTS AFTER RADICAL PROSTATECTOMY. Journal of Urology, 2013, 189, .	0.4	0
100	RAD51 overexpression is a negative prognostic marker for colorectal adenocarcinoma. International Journal of Cancer, 2013, 132, 2118-2126.	5.1	95
101	Loss of CDKN1B/p27Kip1 expression is associated with ERG fusion-negative prostate cancer, but is unrelated to patient prognosis. Oncology Letters, 2013, 6, 1245-1252.	1.8	21
102	High c-MET expression is frequent but not associated with early PSA recurrence in prostate cancer. Experimental and Therapeutic Medicine, 2013, 5, 102-106.	1.8	13
103	Value of cell cycle progression (CCP) score to predict biochemical recurrence and definitive post-surgical pathology Journal of Clinical Oncology, 2013, 31, 5043-5043.	1.6	2
104	991 THE RATE OF ADVERSE DISEASE AND BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY IN PATIENTS ELIGIBLE FOR ACTIVE SURVEILLANCE. Journal of Urology, 2012, 187, .	0.4	0
105	375 FROZEN SECTION NAVIGATED RADICAL PROSTATECTOMY SIGNIFICANTLY INCREASE THE FREQUENCY OF NERVE-SPARING WITHOUT COMPROMISING ONCOLOGICAL OUTCOME. Journal of Urology, 2012, 187, .	0.4	0
106	380 FUNCTIONAL AND ONCOLOGICAL OUTCOME OF PATIENTS YOUNGER THAN 50 YEARS TREATED WITH RADICAL PROSTATECTOMY FOR CLINICALLY LOCALIZED PROSTATE CANCER IN A NON SCREENED EUROPEAN POPULATION. Journal of Urology, 2012, 187, .	0.4	0
107	1361 RADICAL RETROPUBIC PROSTATECTOMY IS POSSIBLE WITH GOOD FUNCTIONAL RESULTS IN PATIENTS WITH PARKINSONS DISEASE OR STATUS POST STROKE. RESULTS FROM MORE THAN 13000 PATIENTS. Journal of Urology, 2012, 187, .	0.4	0
108	689 PATIENTS WITH LOW RISK FEATURES, OMITTED PELVIC LYMPH NODE DISSECTION (PLND) BUT PATHOLOGICALLY LOCALLY ADVANCED PROSTATE CANCERS (PT3A/PT3BNX) HAVE A BETTER ONCOLOGICAL OUTCOME THAN THEIR PT3A/PT3B PNO-COUNTERPARTS. Journal of Urology, 2012, 187, .	0.4	0

#	Article	IF	CITATIONS
109	1342 RELATIONSHIP BETWEEN BLOOD LOSS, BLOOD TRANSFUSION AND BIOCHEMICAL RECURRENCE- RATES: ASSESSMENT OF 17347 RADICAL PROSTATECTOMY PATIENTS. Journal of Urology, 2012, 187, .	0.4	O
110	1640 USE OF PROERECTILE MEDICATION IS A SIGNIFICANT INDEPENDENT RISK FACTOR FOR PSA RECURRENCE IN PATIENTS AFTER RADICAL PROSTATECTOMY. Journal of Urology, 2012, 187, .	0.4	0
111	Role of cyclin D1 amplification and expression in vulvar carcinomas. Human Pathology, 2012, 43, 1386-1393.	2.0	16
112	HPV status in patients with head and neck of carcinoma of unknown primary site: HPV, tobacco smoking, and outcome. Oral Oncology, 2012, 48, 1178-1184.	1.5	71
113	Genomic Deletion of PTEN Is Associated with Tumor Progression and Early PSA Recurrence in ERG Fusion-Positive and Fusion-Negative Prostate Cancer. American Journal of Pathology, 2012, 181, 401-412.	3.8	278
114	Y chromosome losses are exceedingly rare in prostate cancer and unrelated to patient age. Prostate, 2012, 72, 898-903.	2.3	9
115	Neurovascular Structure-adjacent Frozen-section Examination (NeuroSAFE) Increases Nerve-sparing Frequency and Reduces Positive Surgical Margins in Open and Robot-assisted Laparoscopic Radical Prostatectomy: Experience After 11 069 Consecutive Patients. European Urology, 2012, 62, 333-340.	1.9	213
116	Intratumoral <scp>T</scp> but not <scp>B</scp> lymphocytes are related to clinical outcome in prostate cancer. Apmis, 2012, 120, 901-908.	2.0	77
117	Risk assessment of metastatic recurrence in patients with prostate cancer by using the Cancer of the Prostate Risk Assessment score: results from 2937 European patients. BJU International, 2012, 110, 1714-1720.	2.5	12
118	Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma. Cancer, 2012, 118, 1268-1275.	4.1	48
119	Abstract 3291: Defining the role of the cellular polarity regulator Scrib in epithelial tumorigenesis. , 2012, , .		0
120	609 TMPRSS2-ERG GENE FUSION IS STRONGLY ASSOCIATED WITH ELEVATED ANDROGEN RECEPTOR EXPRESSION IN EARLY PROSTATE CANCER. Journal of Urology, 2011, 185, .	0.4	0
121	Brachyury expression predicts poor prognosis at early stages of colorectal cancer. European Journal of Cancer, 2011, 47, 1080-1085.	2.8	72
122	Role of TP53 Mutations in Vulvar Carcinomas. International Journal of Gynecological Pathology, 2011, 30, 497-504.	1.4	49
123	Miliary Never-Smoking Adenocarcinoma of the Lung: Strong Association with Epidermal Growth Factor Receptor Exon 19 Deletion. Journal of Thoracic Oncology, 2011, 6, 199-202.	1.1	54
124	The impact of the number of cores on tissue microarray studies investigating prostate cancer biomarkers. International Journal of Oncology, 2011, 40, 261-8.	3.3	22
125	Overexpression of carbonic anhydrase IX (CAIX) is an independent unfavorable prognostic marker in endometrioid ovarian cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 459, 193-200.	2.8	67
126	Characterization of Enterobacter cloacae Pneumonia: A Single-Center Retrospective Analysis. Lung, 2011, 189, 475-483.	3.3	8

#	Article	IF	CITATIONS
127	ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy. Clinical Cancer Research, 2011, 17, 5878-5888.	7.0	232
128	SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia. Journal of Clinical Investigation, 2011, 121, 4257-4267.	8.2	153
129	19q13 amplification is associated with high grade and stage in pancreatic cancer. Genes Chromosomes and Cancer, 2010, 49, 569-575.	2.8	25
130	1426 TPD52 AS "8Q AMPLIFICATION TARGET" WITH STRONG PROGNOSTIC RELEVANCE IN PROSTATE CA Journal of Urology, 2010, 183, .	NCER. 0.4	0
131	Quality Aspects of TMA Analysis. Methods in Molecular Biology, 2010, 664, 17-26.	0.9	8
132	Abstract 334: Comparison of an in situ hybridization technique based on fluorescence (FISH) with dual color silver-enhanced ISH (SISH) for the validation of equivocal (borderline) status of HER2 (erbb2) in invasive breast carcinoma., 2010,,.		0
133	Phytochelatin Synthesis Is Essential for the Detoxification of Excess Zinc and Contributes Significantly to the Accumulation of Zinc Â. Plant Physiology, 2009, 149, 938-948.	4.8	201
134	INVESTIGATION OF CA9 EXPRESSION IN PULMONAL METASTATIC LESIONS FROM PATIENTS WITH CLEAR CELL RENAL CELL CARCINOMA. Journal of Urology, 2008, 179, 136-136.	0.4	2
135	Vacuolar sequestration of glutathioneS-conjugates outcompetes a possible degradation of the glutathione moiety by phytochelatin synthase. FEBS Letters, 2006, 580, 6384-6390.	2.8	61